Precision BioSciences Issues Update Regarding Recent U.S. Patent Office Action Concerning Cellectis’ Patents

Precision filed requests seeking reexamination of U.S. Patent No. 7,214,536 (the ‘536 patent) and U.S. Patent No. 6,833,252 (the ‘252 patent) on the grounds that these claims of these patents are obvious in view of a variety of references which had not been previously considered by the patent examiners. On May 27, 2009, the PTO granted Precision’s requests and issued initial rejections of all 17 claims of the ‘536 patent, and 18 of 19 claims of the ‘252 patent.

In rejecting the claims of the ‘252 patent, the PTO concluded:

The PTO went on to conclude:

Similar claim terms are used in the ‘605 patent and ‘545 patent that are the subject of ongoing litigation between Cellectis and Precision.

The enzymes which are the basis of Precision’s Directed Nuclease Editor™ technology are genetically-engineered endonucleases with altered specificities. The recognition sites of these rationally-designed enzymes do not include the intron insertion site of a naturally-occurring Group I intron encoded endonuclease.

In rejecting all but one of the claims of the ‘536 patent and the ‘252 patent as obvious, the PTO relied on a number of the same references that Precision contends also render the asserted claims of the ‘605 patent and ‘545 patent obvious or anticipated.

According to data released by the PTO for all inter partes reexaminations which had been concluded since the procedure was first introduced in 1999 through March 31, 2009, 73% of the reexaminations resulted in all issued claims being canceled, and 93% of the reexaminations resulted in at least some issued claims being canceled or amended.

Precision BioSciences is now evaluating whether or not it will request that every patent in this family be reexamined, including those currently asserted against Precision.

Interested parties can download a copy of the PTO’s office actions at: www.precisionbiosciences.com/news.

About Precision BioSciences

Precision's mission is to utilize its engineered endonuclease technology to become the world leader in the field of genomic molecular biology. Precision’s proprietary Directed Nuclease Editor^TM (DNE) technology enables the production of custom genome editing enzymes that can insert, remove, modify, and regulate essentially any gene in mammalian or plant cells.

Precision BioSciences has already produced hundreds of custom endonucleases for partners and internal development that can precisely alter naturally occurring sequences within genomes. Precision has successfully partnered its DNE technology with several of the world’s largest agbiotech firms and is internally developing applications in biological production and human therapeutics. For additional information, please visit www.precisionbiosciences.com.

Precision BioSciences, Inc.
Chelsea Lynam, 919-314-5512